Indian Immunologicals Limited

16/01/2026

We are participating in PEDICON 2026 !

Join us, as we continue our journey of advancing child health with trusted, indigenous vaccines.

📍 Stall No. G18
📅 17–20 January 2026
📍 Biswa Bangla Convention Centre, Kolkata.

Let’s come together and shape a healthier future for children.

07/01/2026

Dr K Anand Kumar, Managing Director, IIL, met Mr Vijay Nehra, Joint Secretary , Ministry of Health and Family Welfare, and briefed him about the contribution of IIL in nation achieving self sufficiency in the field of vaccines. Other senior persons from IIL - Mr Mukul Gaur, Dr NSN Bhargav, Sr VP, Mr Sarthak Vasudeva, Sr VP were also present.

02/01/2026

Indian Immunologicals Limited (IIL) a wholly owned subsidiary of the National Dairy Development Board (NDDB) congratulates Dr Meenesh C Shah, Chairman (NDDB and IIL) on his appointment for 3.5 years as Chairman of NDDB by Government of India.

His exemplary leadership in the field of dairying, sustainability and organisational excellence will continue to show way in strengthening cooperatives in the world’s largest country for dairying.

His compassion and care as Chairman of IIL and Pristine, New Zealand has guided our companies and enabled stay composed and perform exceedingly well during our difficult times.

This recognition by the Government of India to extend the services of Dr Meenesh C Shah as Chairman of NDDB will also consolidate NDDB and it’s subsidiaries in adding immense value to the nation in realising the dream of Viksit Bharat 2047.

27/12/2025

'Isolated Incident': Indian Immunologicals Limited Issues Clarification After Australia's Advisory On Counterfeit Anti-Rabies Vaccine Abhayrab

Source: The Free Press Journal | Date: December 27, 2025
Click on the article below to know more:

Indian Immunologicals Limited clarified concerns over counterfeit Abhayrab after an Australian advisory, saying reports relate to a single batch identified in January 2025. The Hyderabad-based firm called it an isolated incident, confirmed the batch is off shelves and said all vaccines are tested by...

27/12/2025

Abhayrab Controversy: Clarifying the Counterfeit Vaccine Concerns

Source: Devdiscourse | Date: December 27, 2025
Click on the article below to know more:

Indian Immunologicals Limited clarifies concerns about a counterfeit batch of its rabies vaccine, Abhayrab, following an advisory by Australia. The issue involves a specific batch from 2024, with no broader risk identified. IIL urges a review of the advisory to prevent public mistrust.

27/12/2025

Fake Rabies Vaccine Advisory Explained: What Australia Warned, What India Clarified

Source: NDTV | Date: December 27, 2025
Click on the article below to know more:

A recent Australian advisory suggested that counterfeit rabies vaccines were circulating in India. The Indian makers of Abhayrab have now rejected these claims.

27/12/2025

Over-cautionary Manufacturer on Australia's advisory against its rabies vaccine.

Source: THEWEEK | Date: December 27, 2025
Click on the article below to know more:

New Delhi, Dec 27 (PTI) Days after Australia issued an advisory against counterfeit rabies vaccine in India, a public sector

27/12/2025

Australia issues advisory on counterfeit anti-rabies vaccine in India; pharma refutes charges. Indian Immunologicals Limited says the vaccine batch is no longer in circulation.

Source: TheHindu | Date: December 27, 2025
Click on the article below to know more:

Australian government warns of counterfeit rabies vaccine in India; Indian Immunologicals clarifies the issue is resolved and batch is withdrawn.

24/12/2025

We are happy to share that Indian Immunologicals Limited (IIL) has been awarded for Innovation – Human Health Product of the Year (Havisure), India’s first and only indigenous Hepatitis A vaccine.

In addition an award for being the Best in Veterinary Healthcare Vaccines was also given at the Hybiz Tv Business Excellence Awards Function held at the HICC Novotel in Hyderabad. This reaffirms IIL’s leadership across both human and animal health segments.

The evening celebrated organizations that lead, innovate and set new benchmarks for the industry, along with visionaries who have shaped healthcare in India. Gracing the occasion as Guest of Honour, Dr. K. Anand Kumar, Managing Director, IIL, highlighted the organization’s unwavering commitment to public health, indigenous vaccine development, and affordable access to life-saving immunization. Dr. Kumar emphasized that innovations like Havisure reflect IIL’s broader mission of contributing to India’s self-reliance in vaccines. He also underscored the crucial role of IIL’s veterinary healthcare segment in safeguarding animal health, supporting farmers’ livelihood strengthening the One Health Initiative .

Representing IIL at the event were Mr. Sarthak Vasudeva, Sr. Vice President – International Business, Mr. Shakul Srivastava, Vice President – Human Health Business, and Mr. Sobhan Babu, Vice President – Animal Health Business.

National Dairy Development Board

22/12/2025

Indian Immunologicals Limited (IIL) with an impressive growth story has catapulted as one among the top league vaccine companies in India.

Availability, Affordability, Accessibility and Adaptability are inherent in the DNA of IIL, making it as a single largest contributor to vaccine self sufficiency of the nation.

Being one of the largest manufacturers of human and animal vaccines, IIL is a company committed to One Health and balances profitability with social good, a unique model in the vaccine industry.

Outlook Publishing (Outlookindia) Pvt Ltd carried an in depth article on Indian Immunologicals Limited and an exclusive interview with Dr K Anand Kumar, MD, IIL, which highlights the significant achievements of IIL and It’s service to the nation. This article was published along side article on National Dairy Development Board and its other subsidiaries.

19/12/2025

Indian Immunologicals Limited (IIL) Honoured for Excellence in Healthcare Innovation!

IIL has been recognized by the Confederation of Indian Industry (CII) at the ‘CII Industrial Innovation Awards 2025 : Top 100 Innovative Company’, chosen from leading sectors, including healthcare, IT, defence, aerospace, power, engineering, automobile, telecom, FMCG and others.

The award was presented during the ‘CII Global Summit on Technology, R&D and Intellectual Property’ in New Delhi held during 16 - 17 December 2025, themed ‘From Dependence to Dominance: Research, Deep Tech, and IP for AtmaNirbhar Bharat’. Dr. Santosh B Ghadage, Sr. Vice President - Mfg. had the privilege of accepting the award on behalf of IIL.

This recognition was conferred to IIL for its development of indigenous healthcare solutions like Havisure, India’s first indigenously developed Hepatitis A vaccine, which addresses critical public health need and reduces the country's reliance on imported vaccines; and for developing the vaccine against Infectious Bovine Rhinotracheitis, India’s first gE-deleted DIVA marker vaccine for this disease, which contributes to improving dairy productivity and enhancing farmer welfare.

The event brought together industry leaders, policymakers, academia, and research institutes, fostering discussions on innovation, R&D, and India’s journey toward self-reliance.

This award is a testament to:

-The visionary leadership of our Managing Director, Dr. K. Anand Kumar, which fosters a culture of scientific rigor and innovation.
-The capabilities of our manufacturing and R&D teams.
-Commitment to national healthcare priorities.

Congratulations to the entire IIL team on this continued recognition of excellence!

National Dairy Development Board